| Project/Area Number |
16K19074
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Abe Hiroyuki 東京大学, 医学部附属病院, 助教 (40708632)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 胃癌 / EBV / ARID1A / EZH2 / Epstein-Barr virus / 病理学 / 癌 / ウィルス |
|---|
| Outline of Final Research Achievements |
I studied the role of ARID1A and EZH2 in gastric cancer (especially EBV-associated gastric cancer) with in vitro experiments and morphological analyses of surgical specimens. First, microarray analyses disclosed that knockdown of ARID1A in gastric cancer cell line induced expression change of genes related to cell proliferation and DNA synthesis. Second, I found that non-tumor background mucosa in the surgically resected specimen of gastric cancer harbored some small foci with loss of ARID1A expression, which might be a precursor lesion of EBV-associated gastric cancer. Third, in vitro analyses revealed EZH2 induced STAT3 methylation in an EBV-infected gastric cancer cell line. Lastly, clinicopathological analyses revealed overexpression of EZH2 is a poor prognositic factor in EBV-associated gastric carcinoma.
|
